查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552564

癌症基因治疗市场规模、份额和趋势分析报告：按治疗、按最终用途、按地区、细分市场预测，2024-2030年

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

癌症基因治疗市场的成长与趋势：

Grand View Research, Inc. 的最新报告显示，到 2030 年，全球癌症基因治疗市场预计将达到 127.6 亿美元。

由于全球对新疗法的需求不断增加以及全球癌症发生率不断上升，预计 2024 年至 2030 年该市场的复合年增长率将达到 18.9%。而且，该治疗方法为各类遗传性和诱发性癌症提供了绝对的解决方案，使其成为作为癌症治疗药物更理想的选择。例如，Kite 的 Tecartus (brexucabtagene autoleucel) 已获得 FDA核准用于治疗復发性或难治性 B 细胞前驱急性淋巴细胞白血病。

恶性的盛行率在全球范围内不断增加，预计这将推动对有效治疗和各种策略的需求，以应对日益增加的恶性发病率。此外，市场的技术进步预计将为新型疗法提供新的机会。因此，产品核准的数量正在增加。例如，2022年3月，欧洲医疗机构建议给予Carvykti（ciltacabtagene autoleucel）有条件行销核准，用于治疗復发性和难治性多发性骨髓瘤。

该市场受到世界各国政府和国家癌症协会的积极支持的积极推动。人们越来越关注增加癌症基因治疗的研究经费。例如，2021 年 12 月，荷兰平台 DARE-NL（荷兰）获得了 KWF 荷兰癌症协会 520 万美元的津贴。这笔津贴将使 DARE-NL 能够推进针对贫困人群的细胞和基因治疗策略。

亚洲製造商专注于可大量生产的较不复杂的分子，因此对新的复杂技术的投资相对较少。因此，投资高产量、低成本技术是欧洲和北美等其他已开发地区製造商避免竞争压力的一种选择。

市场上运营的主要公司都专注于开发强大的癌症基因治疗药物的合作研究。例如，2022年8月，Gensaic与Ovid Therapeutics达成合作研究协议，利用专有的噬菌体衍生粒子基因治疗平台开发多达三种中枢神经系统适应症的基因药物。

癌症基因治疗市场报告亮点

  • 随着对基因层面上癌症病理学认识的进步以及对基因诱导免疫疗法和个人化医疗的需求的增加，市场正处于一个重要的转折点。
  • 由于基因诱导免疫治疗研究的进展，2023年基因诱导免疫治疗领域占最大市场。
  • 由于对新型基因疗法的需求不断增长以及 FDA核准癌症基因疗法的数量不断增加，生物製药公司在 2023 年占据了最大的市场占有率。由于该领域研发活动的增加，生物製药公司预计在预测期内将成长最快。
  • 由于关键参与者的存在以及政府和国家癌症研究所加强支持以推进该地区的癌症研究，北美将在 2023 年占据市场主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章癌症基因治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 癌症基因治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章癌症基因治疗市场：依治疗方法估算与趋势分析

  • 细分仪表板
  • 癌症基因治疗市场：治疗波动分析
  • 癌症基因治疗市场：依治疗分类的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 溶瘤病毒疗法
  • 基因诱导的免疫治疗
  • 基因转移

第五章癌症基因治疗市场：依最终用途的估计和趋势分析

  • 细分仪表板
  • 癌症基因治疗市场：最终用途变异分析
  • 癌症基因治疗市场：依最终用途分類的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 建筑机构
  • 生物製药公司
  • 诊断中心
  • 其他的

第六章癌症基因治疗市场：按治疗方法和最终用途分類的区域估计和趋势分析

  • 区域仪表板
  • 癌症基因治疗市场：区域差异分析
  • 癌症基因治疗市场：按技术和最终用途进行区域估计和趋势分析
  • 2018-2030年市场规模、预测及趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他国家

第七章 竞争格局

  • 市场参与企业分类
  • 主要企业简介
    • Abeona Therapeutics Inc.
    • Asklepios BioPharmaceutical Inc.
    • Altor Bioscience Inc.
    • Bluebird bio Inc.
    • BioCancell Inc.
    • CelgeneInc.
    • Elevate BioInc.
    • GlaxoSmithKlineInc.
    • Genelux Corporation
    • GenVec
    • Introgen TherapeuticsInc.
    • OncoGenex Pharmaceuticals Inc.
Product Code: GVR-4-68039-984-2

Cancer Gene Therapy Market Growth & Trends:

The global cancer gene therapy market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.9% from 2024 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

  • The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine
  • The gene induced immunotherapy segment held the largest share in 2023 due to increase in the advancement in gene induced immunotherapy research
  • Biopharmaceutical companies held the largest market share in 2023 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field
  • North America dominated the market in 2023 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Gane Therapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High growth of the pharmaceutical industry
      • 3.2.1.2. Rising R&D investments and demand for novel cancer therapeutics
      • 3.2.1.3. Increased incidence of cancers
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High product prices
      • 3.2.2.2. Unethical use of gene therapy
  • 3.3. Cancer Gene Therapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gane Therapy Market: Therapy Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cancer Gene Therapy Market: Therapy Movement Analysis
  • 4.3. Cancer Gene Therapy Market by Therapy Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Oncolytic Virotherapy
    • 4.5.1. Oncolytic Virotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Gene Induced Immunotherapy
    • 4.6.1. Gene Induced Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Gene Transfer
    • 4.7.1. Gene Transfer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cancer Gene Therapy Market: End Use Movement Analysis
  • 5.3. Cancer Gene Therapy Market by End Use Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Research Institutes
    • 5.5.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Biopharmaceutical Companies
    • 5.6.1. Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Diagnostic Centers
    • 5.7.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Therapy and End Use

  • 6.1. Regional Dashboard
  • 6.2. Regional Cancer Gene Therapy Market Movement Analysis
  • 6.3. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Technology & End Use
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. North America
    • 6.5.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement scenario
      • 6.5.2.5. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement scenario
      • 6.5.3.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement scenario
      • 6.5.4.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. UK
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement scenario
      • 6.6.2.5. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement scenario
      • 6.6.3.5. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Switzerland
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement scenario
      • 6.6.4.5. Switzerland Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Japan
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement scenario
      • 6.7.2.5. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement scenario
      • 6.7.3.5. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Competitive Scenario
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. Reimbursement scenario
      • 6.7.4.5. Australia Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Rest of World
    • 6.8.1. Latin America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Key Company Profiles
    • 7.2.1. Abeona Therapeutics Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Asklepios BioPharmaceutical Inc.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Altor Bioscience Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Bluebird bio Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. BioCancell Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. CelgeneInc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Elevate BioInc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. GlaxoSmithKlineInc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Genelux Corporation
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. GenVec
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Introgen TherapeuticsInc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. OncoGenex Pharmaceuticals Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 4 Global cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 North America cancer gene therapy market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 North America cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 9 U.S. cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 Canada cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Mexico cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 13 Mexico cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 16 Europe cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 UK cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 18 UK cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Germany cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 20 Germany cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 Switzerland cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 22 Switzerland cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 24 Asia Pacific cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 25 Asia Pacific cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Japan cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 27 Japan cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 China cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 29 China cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Australia cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 31 Australia cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Rest of World cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 33 Rest of World cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement Primary Research Pattern
  • Fig. 2 Market Research Approaches
  • Fig. 3 Value Chain-Based Sizing & Forecasting
  • Fig. 4 Market Formulation & Validation
  • Fig. 5 Market driver analysis
  • Fig. 6 Market restraint analysis
  • Fig. 7 PESTEL Analysis
  • Fig. 8 Porter's Five Forces Analysis
  • Fig. 9 Cancer gene therapy market, therapy outlook key takeaways (USD Million)
  • Fig. 10 Cancer gene therapy market: Therapy movement analysis 2023 & 2030 (USD Million)
  • Fig. 11 Oncolytic Virotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 12 Gene induced immunotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 Gene transfer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Cancer gene therapy market, end use outlook key takeaways (USD Million)
  • Fig. 15 Cancer gene therapy market: End use movement analysis (USD Million), 2023 & 2030
  • Fig. 16 Research institutes market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Biopharmaceutical companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Diagnostic centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Cancer gene therapy market: Regional key takeaways (USD Million)
  • Fig. 21 Cancer gene therapy market: regional outlook, 2023 & 2030 (USD Million)
  • Fig. 22 North America cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Switzerland cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Asia Pacific cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 China cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Japan cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Australia cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Rest of World cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)